Skip to main content
NRXP logo

NRx Pharmaceuticals, Inc.

NRXPNASDAQHealthcareBiotechnology

$2.60Today:- (-)1Y −14.78%

As of Oct 16, 2026 close

Market cap
$102.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.62$5.06
Volume (live)
-
Avg. volume (3M)
684.66K

NRx Pharmaceuticals, Inc. (NRXP) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for NRx Pharmaceuticals, Inc. stock.

Analyst Consensus Rating

Investment consensus from 4 professional research analysts

Consensus Rating

Buy
Based on 4 unique analysts
(5 total ratings in last 90 days)
Low Confidence3.0:1 Buy/Sell

Average Price Target

$35.00
+1246.15% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest NRXP Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Edward Woo
Ascendiant
BuyMaintains
$49.00 → $50.00
Zacks Equity Research
Zacks Equity Research
SellInitiates Coverage
-
Patrick Trucchio
HC Wainwright
BuyReiterates
$45.00
Thomas Shrader
BTIG
BuyMaintains
$10.00
Zacks Equity Research
Zacks Equity Research
HoldInitiates Coverage
-

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Sep 30, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for NRXP?

The analyst consensus rating for NRXP is Buy, based on the latest ratings from 4 analysts over the last 90 days.

What is the average price target for NRXP?

The average 12-month price target for NRXP is $35.00, representing an upside of 1246.2% from the Oct 16, 2026 close of $2.60.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.